as 05-14-2025 4:00pm EST
vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Its product pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.
Founded: | 2015 | Country: | United States |
Employees: | N/A | City: | HIGH POINT |
Market Cap: | 56.7M | IPO Year: | 2015 |
Target Price: | $35.50 | AVG Volume (30 days): | 9.3K |
Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -3.20 | EPS Growth: | N/A |
52 Week Low/High: | $12.12 - $29.01 | Next Earning Date: | 05-27-2025 |
Revenue: | $1,017,000 | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
VTVT Breaking Stock News: Dive into VTVT Ticker-Specific Updates for Smart Investing
Zacks
2 months ago
Associated Press Finance
2 months ago
GlobeNewswire
2 months ago
Clinical Trials Arena
2 months ago
GuruFocus.com
2 months ago
GuruFocus.com
2 months ago
MT Newswires
2 months ago
GlobeNewswire
2 months ago
The information presented on this page, "VTVT vTv Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.